AGY Stock Overview
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments.
Allergy Therapeutics plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.19|
|52 Week High||UK£0.41|
|52 Week Low||UK£0.16|
|1 Month Change||10.00%|
|3 Month Change||-12.50%|
|1 Year Change||-33.62%|
|3 Year Change||63.83%|
|5 Year Change||-33.04%|
|Change since IPO||-74.16%|
Recent News & Updates
|AGY||GB Pharmaceuticals||GB Market|
Return vs Industry: AGY underperformed the UK Pharmaceuticals industry which returned 5.2% over the past year.
Return vs Market: AGY underperformed the UK Market which returned -9% over the past year.
|AGY Average Weekly Movement||3.7%|
|Pharmaceuticals Industry Average Movement||6.4%|
|Market Average Movement||5.4%|
|10% most volatile stocks in GB Market||10.8%|
|10% least volatile stocks in GB Market||2.7%|
Stable Share Price: AGY is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: AGY's weekly volatility (4%) has been stable over the past year.
About the Company
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut.
Allergy Therapeutics plc Fundamentals Summary
|AGY fundamental statistics|
Is AGY overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AGY income statement (TTM)|
|Cost of Revenue||UK£23.10m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0083|
|Net Profit Margin||-6.81%|
How did AGY perform over the long term?See historical performance and comparison